RxDoctor Payments Data

Betty Banh, PA

Physician Assistant · Phoenix, AZNPI 1215660394

Payments from drug & device makers

$4,641in general payments, 2019–2025

Across 173 payments — averaging $26.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Progenics Pharmaceuticals, Inc.$519
  • Sumitomo Pharma America, Inc.$487
  • Johnson & Johnson$419
  • Dendreon Pharmaceuticals LLC$355
  • AbbVie$315
  • Blue Earth Diagnostics$216
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,36394%
  • Education$2786%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,641 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$119,274
Medicare patients
434
Services billed
11,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide30$455,339
MyrbetriqMirabegron80$63,936
GemtesaVibegron51$39,563
Testosterone54$8,149
Tamsulosin Hcl239$3,719
Fesoterodine Fumarate ErFesoterodine Fumarate23$3,331
Testosterone Cypionate60$2,773
Methenamine Hippurate15$1,896
Finasteride107$1,682
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$1,519
Solifenacin Succinate41$1,428
Potassium Citrate ErPotassium Citrate16$1,385
Dutasteride29$1,339
Desmopressin Acetate24$1,164
Oxybutynin Chloride ErOxybutynin Chloride41$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$154$519,275110 claims
Sumitomo Pharma America, Inc.Gemtesa$487$39,56351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →